Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
GLP-1 secretion in response to meals is dramatically increased after gastric bypass operations. GLP-1 is a powerful insulinotropic and anorectic hormone, and analogs of GLP-1 are widely used for the treatment of diabetes and recently approved also for obesity treatment. It is, therefore, reasonable to assume that the exaggerated GLP-1 secretion contributes to the antidiabetic and anorectic effects of gastric bypass. Indeed, human experiments with the GLP-1 receptor antagonist, Exendin 9-39, have shown that the improved insulin secretion, which is responsible for part of the antidiabetic effect of the operation, is reduced and or abolished after GLP-1 receptor blockade. Also the postoperative improvement of glucose tolerance is eliminated and or reduced by the antagonist, pointing to a key role for the exaggerated GLP-1 secretion. Indeed, there is evidence that the exaggerated GLP-1 secretion is also responsible for postprandial hypoglycemia sometimes observed after bypass. Other operations (biliopancreatic-diversion and or sleeve gastrectomy) appear to involve different and/or additional mechanisms, and so does experimental bariatric surgery in rodents. However, unlike bypass surgery in humans, the rodent operations are generally associated with increased energy metabolism pointing to an entirely different mechanism of action in the animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Pories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293 · cited 2×
“[4] Pories WJ, Swanson MS, MacDonald KG, et al.”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“[15] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundResultSelf-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“healthy controls [9], to the extent that GLP-1 agonists can be used for diabetes therapy [10].”
BackgroundSelf-citationRoux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
FXR is a molecular target for the effects of vertical sleeve gastrectomy
Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H. E., Sandoval, D. A., Kohli, R., Bäckhed, F., et al. (2014) · Nature · doi:10.1038/nature13135 · Cited by 931
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“GLP-1 is metabolized immediately after its release by the enzyme, dipeptidylpeptidase-4 (DPP-4) [30], which cleaves off the N-terminal dipeptide leaving a metabolite (GLP-1 9–36 amide), which is devoid of insulinotropic activity.”
BackgroundSelf-citationHyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.
Service, G. J., Thompson, G. B., Service, F. J., Andrews, J. C., Collazo-Clavell, M. L., & Lloyd, R. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043690 · Cited by 779
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741 · cited 4×
“Similar observations were made by le Roux et al. in a series of studies from the Hammersmith Hospital, Imperial College, London [6,7].”
BackgroundInfluentialEnteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591 · cited 2×
“Bile acids are elevated after the bypass operations in many patients [59] and have been suggested to play role by interacting with nuclear farnesoid X receptor (FXR) or membraneassociated bile acid receptors (TGR5) [60], but changes in circulating bile acid concentrations do not occur until 3 months after the operatio…”
BackgroundGoldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377 · cited 2×
“[3] Goldfine AB, Mun EC, Devine E, et al.”
BackgroundSelf-citationPatti, M. E., McMahon, G., Mun, E. C., Bitton, A., Holst, J. J., Goldsmith, J., Hanto, D. W., Callery, M., Arky, R., Nose, V., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1933-x · Cited by 365
Self-citationKorner, J., Bessler, M., Inabnet, W., Taveras, C., & Holst, J. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.08.004 · Cited by 344 · cited 3×
“The secretion of glucose-dependent insulinotropic polypeptide (GIP) may be slightly increased or slightly decreased and shows no consistent pattern [2,29].”
BackgroundSelf-citationSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323 · cited 1×
“[53] Salehi M, Prigeon RL, D'Alessio DA.”
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313 · cited 3×
“[49] Jorgensen NB, Jacobsen SH, Dirksen C, et al.”
BackgroundBlockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass
Salehi, M., Gastaldelli, A., & D'Alessio, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.044 · Cited by 289
Odstrcil, E. A., Martinez, J. G., Santa Ana, C. A., Xue, B., Schneider, R. E., Steffer, K. J., Porter, J. L., Asplin, J., Kuhn, J. A., & Fordtran, J. S. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29870 · Cited by 209
Dirksen, C., Damgaard, M., Bojsen‐Møller, K. N., Jørgensen, N. B., Kielgast, U., Jacobsen, S. H., Naver, L. S., Worm, D., Holst, J. J., Madsbad, S., et al. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12087 · Cited by 184 · cited 2×
“[39] Dirksen C, Damgaard M, Bojsen-Moller KN, et al.”
BackgroundMcLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1628 · Cited by 183
Self-citationExaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia
Toft-Nielsen, M., Madsbad, S., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250051049 · Cited by 132 · cited 2×
“Accordingly, in model experiments where the glucose and GLP-1 responses to oral glucose were mimicked by intravenous infusion, it was possible to provoke a rather severe hypoglycemia [25].”
BackgroundSelf-citation
Cited by
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Glucose transporters in the small intestine in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02439-5 · Cited by 290
Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine
Sun, E. W., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S. L., Wattchow, D. A., Rayner, C. K., Deane, A. M., Young, R. L., et al. (2017) · Diabetes · doi:10.2337/db17-0058 · Cited by 152
“Furthermore, there is increasing acceptance of the notion that the metabolic benefits of gastric bypass surgeries are partly attributable to the elevation of GLP-1 levels (3).”
BackgroundWeight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Perakakis, N., Kokkinos, A., Peradze, N., Tentolouris, N., Ghaly, W., Pilitsi, E., Upadhyay, J., Alexandrou, A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153997 · Cited by 93
Metadata
- Authors
- Holst, J. J., & Madsbad, S.
- Venue
- Surgery for Obesity and Related Diseases
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 12
- Issue
- 6
- Pages
- 1236-1242
- ISSN
- 1550-7289 (ISSN-L)
- OpenAlex
- W2289963474
- Cited by
- 67
- References
- 22
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.